Hikma Pharmaceuticals : First Jordanian Site to Receive ISO 50001 Certification

Amman, 16 February 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announced that it has attained the ISO 50001 certification in recognition of its dedication to improving its energy management system (EnMS) over the past three years for its Jordan manufacturing operations. This achievement positions Hikma as the first pharmaceutical company in the Middle East and the first Jordanian site to obtain the ISO 50001 certification, which enables organizations to continually enhance energy performance, efficiency, use and consumption.

The certification was granted following a comprehensive on-site inspection and thorough evaluation process covering Hikma's energy management documents, procedures and upcoming strategy for 2015.

In addition to the ISO 50001 for energy management, Hikma had previously attained the ISO 9001 for quality management, ISO 14001 for environmental management, as well as the OHSAS 18001 for occupational health and safety.

Furthermore, Hikma periodically reports on various gas emissions and environmental outputs to demonstrate how it is improving its impact on the environment and aligning its operations to international standards. These reports are submitted to global entities such as the United Nations Global Compact, Carbon Disclosure Project and Global Reporting Initiative.

Mazen Darwazeh, Vice Chairman, President and CEO, MENA and Emerging Markets of Hikma said: "Being the first Jordanian site to receive the ISO 50001 certification is a distinct honor that spurs us to do all that is in our power to ensure that Hikma continues to carry out eco-friendly operations," commented. "Over the past few years, we have been wholly committed to mitigating our energy consumption and gas emissions to reduce our ecological footprint in line with global best practices. By doing so, we have succeeded in establishing an internal culture at Hikma that promotes environmental sustainability and conscientiousness." 

-- ENDS --

About Hikma
Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In December 2013, Hikma had 7,067 employees worldwide.

Enquiries: